Angeles Therapeutics is a next generation cell and immune therapy company. Angeles has developed a novel chimeric antigen receptor T (CAR-T) platform, designated Synthetic Immune Receptor (SIR), that provides physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, the SIR platform is highly effective against solid tumors. Angeles Therapeutics has also developed one of the largest portfolios of CAR-T in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platforms are covered by multiple patent applications, giving us a very strong IP position in this area. Our IP portfolio in this space is also very broad and covers autologous, allogeneic (including insertion at TRAC locus), bispecific, multi-specific and universal targeting approaches. A global pharma company has already tested and validated our platform under an MTA and proven it to be superior to not only the current generation CAR-T in clinical use but also a next generation CAR-T currently in development. Angeles is in partnership discussions with several major pharmaceutical companies and is looking for additional partnership opportunities for further development of its portfolio. We are also pursuing several assets internally. Dr. Chaudhary's academic research laboratory has received nearly $10.0M in peer-reviewed funding from CIRM (California Institute for Regenerative Medicine) and DoD (Department of Defense) to develop 6 SIR-T programs for solid tumors and a bispecific SIR-T for lymphoma. In addition to the SIR platform, Angeles Therapeutics has developed several novel platforms and tools for next generation cell therapies, including next generation CAR-NK platforms, platforms for stem-like T-cell isolation, gene transfer, cell expansion, co-stimulation, control of CAR-T/NK activity, suicide switches, and potency assays.
Copyright © 2021 Angeles Therapeutics, Inc - All Rights Reserved.